Researchers have now investigated this phenomenon further. Of 709 patients treated with balicatib, nine developed skin hardening and were diagnosed with morphea-like skin changes. Patients taking the lowest dose of balicatib or placebo did not did experience skin hardening. Discontinuation of balicatib resulted in complete resolution of symptoms in eight patients and partial resolution in one. These results suggest that skin hardening is a dose-related adverse effect associated with balicatib.
Runger TM, Adami S, Benhamou CL et al. J Am Acad Dermatol 2011 (article in press)